Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
October 01 2020 - 4:30PM
Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a
biopharmaceutical company focused on the development and
commercialization of therapeutics for central nervous system (CNS)
disorders, today announced the promotion of Dr. Suresh Durgam
to the position of Chief Medical Officer. Additionally, Dr. Andrew
Satlin will step down as Chief Medical Officer, and will leave the
Company effective October 28, 2020 to pursue a new
opportunity.
“Dr. Durgam has a proven track record and deep expertise in
neuropsychiatric drug development and has led our lumateperone
clinical programs, including the schizophrenia and bipolar
depression programs, while also playing a critical role in shaping
our research and development strategy,” said Dr. Sharon Mates,
Chairman and CEO of Intra-Cellular Therapies. “I look
forward to continuing to work with him to advance our pipeline.
Prior to joining Intra-Cellular Therapies, Dr. Durgam led the
clinical development of the antipsychotic cariprazine, which
received approval in schizophrenia and bipolar disorder. I would
like to thank Dr. Satlin for his contributions to the Company and
wish him continued success.”
Dr. Durgam has served as Intra-Cellular Therapies Senior Vice
President, Late Stage Clinical Development and Medical Affairs
since joining the Company in 2018. He has been instrumental in the
success of our schizophrenia and bipolar depression programs. Dr.
Durgam, has over 23 years of experience in clinical research which
includes over 17 years in neuropsychiatric drug development,
including the development of antipsychotics and
antidepressants.
Dr. Durgam served in clinical development leadership roles at
Forest Laboratories, Solvay and Allergan plc. He led programs
across various indications including major depressive disorder,
bipolar mania, bipolar depression, schizophrenia, cognitive
impairment associated with schizophrenia, negative symptoms in
schizophrenia, anxiety disorders, and pain. He has experience in
the U.S. and globally in all phases of drug development from Phase
I through Phase 4 studies. In addition to his role in the
development of cariprazine and its approval in schizophrenia and
bipolar disorder, Dr. Durgam oversaw studies with vilazodone,
levomilancipran, and asenapine that led to sNDA fillings and
supplemental approvals. He also led the major depressive disorder
program with rapastinel and onabotulinumtoxinA for depression.
Dr. Durgam graduated with his medical degree from the Siddhartha
Medical College in India and received his residency training in
psychiatry at Scott & White Clinic and Hospital – Texas A&M
University System College of Medicine.
About Intra-Cellular
TherapiesIntra-Cellular Therapies is a
biopharmaceutical company founded on Nobel prize-winning
research that allows us to understand how therapies affect the
inner-workings of cells in the body. The company leverages this
intracellular approach to develop innovative treatments for people
living with complex psychiatric and neurologic diseases.
ContactIntra-Cellular Therapies, Inc.Juan
Sanchez, M.D.Vice President, Corporate Communications and Investor
Relations646-440-9333
Burns McClellan, Inc.Lisa
Burnsjgrimaldi@burnsmc.com212-213-0006Media Inquiries:
Ana FullmerCorporate Media Relations
W20wcgafullmer@wcgworld.com202-507-0130
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intra Cellular Therapies (NASDAQ:ITCI)
Historical Stock Chart
From Apr 2023 to Apr 2024